Summary by Futu AI
EyePoint Pharmaceuticals officer David S. Jones is set to sell 10,104 shares of common stock on 02/02/2024, as per the latest filing. These shares, valued at an aggregate market value of $288,065.04, were acquired on the same day through the exercise of stock options, with the transaction involving a cash payment to the issuer. This sale follows a series of transactions over the past three months where a total of 72,983 shares were sold, amounting to gross proceeds of $1,753,183.17.